Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Andrea Tan Analyst Performance

Analyst at The Goldman Sachs Group

Andrea Tan is a stock analyst at The Goldman Sachs Group in the medical sector, covering 7 publicly traded companies. Over the past year, Andrea Tan has issued 11 stock ratings, including buy and hold recommendations. While full access to Andrea Tan's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrea Tan's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
17 Last 1 Years
Buy Recommendations
70.59% 12 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy70.6%12 ratings
Hold29.4%5 ratings
Sell0.0%0 ratings

Out of 17 total stock ratings issued by Andrea Tan at The Goldman Sachs Group, the majority (70.6%) have been Buy recommendations, followed by 29.4% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
7 companies

Andrea Tan, an analyst at The Goldman Sachs Group, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Andrea Tan of The Goldman Sachs Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
85.7%
MED - DRUGS
1 company
14.3%

Andrea Tan's Ratings History at The Goldman Sachs Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
2/5/2026Reiterated Rating$63.51$68.00Neutral
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
1/30/2026Boost Price Target$279.34$327.00Buy
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
1/14/2026Reiterated Rating$493.90$571.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
1/7/2026Boost Price Target$64.76$85.00Neutral
Insmed, Inc. stock logo
INSM
Insmed
12/15/2025Boost Price Target$198.40$258.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
11/20/2025Boost Price Target$38.97$48.00Neutral
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
11/6/2025Reiterated Rating$68.15$51.00Neutral
Insmed, Inc. stock logo
INSM
Insmed
10/31/2025Boost Price Target$193.08$225.00Buy
Insmed, Inc. stock logo
INSM
Insmed
10/3/2025Boost Price Target$156.79$196.00Buy
Insmed, Inc. stock logo
INSM
Insmed
8/13/2025Boost Price Target$122.53$142.00Buy
Insmed, Inc. stock logo
INSM
Insmed
6/11/2025Boost Price Target$97.54$112.00Buy
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
5/12/2025Lower Price Target$1.93$8.00Buy
Tarsus Pharmaceuticals, Inc. stock logo
TARS
Tarsus Pharmaceuticals
5/5/2025Boost Price Target$47.61$51.00Neutral
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
4/17/2025Lower Price Target$3.09$16.00Buy
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
3/25/2025Lower Price Target$8.05$27.00Buy
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
3/3/2025Lower Price Target$4.09$19.00Buy
Day One Biopharmaceuticals, Inc. stock logo
DAWN
Day One Biopharmaceuticals
2/10/2025Lower Price Target$11.88$43.00Buy